Company

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform
AbbVieAuto-immune

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma (TYO: 4565) announced that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement with AbbVie (NYSE: ABBV), granting AbbVie exclusive rights to develop…

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Shanghai Henlius Advances Anti‑IL1RAP Antibody HLX109 Toward First‑in‑Human Trial – Australian HREC Approval and TGA CTN Completed for Generalized Pustular Psoriasis

Hybio Pharmaceutical's HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Hybio Pharmaceutical’s HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis
Eli LillyNYSE: LLY

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD
Gilead SciencesKymera Therapeutics

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

SineuGene's ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation
Gene therapyRare / orphan disease drugs

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter
Acotec ScientificCVD

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Show More